Cantor Fitzgerald Reiterates Their Buy Rating on Vital Therapies (VTL)


In a report released yesterday, William Tanner from Cantor Fitzgerald reiterated a Buy rating on Vital Therapies (NASDAQ: VTL), with a price target of $18. The company’s shares closed on Friday at $6.68.

Tanner said:

“: We reiterate the Overweight rating and $18 PT for VTL stock. We believe ELAD could be an important treatment for severe alcoholic hepatitis (sAH) and view forthcoming release of top-line data from the VTL-308 trial as a major stock-moving event. We view the release as a binary event but acknowledge that there may be some possibility for equivocal results to emerge. Any outcome other than unequivocally positive data will not be positive for the stock, in our opinion.”

According to TipRanks.com, Tanner is a 3-star analyst with an average return of 3.3% and a 48.4% success rate. Tanner covers the Healthcare sector, focusing on stocks such as Supernus Pharmaceuticals, Intra-Cellular Therapies, and Aquinox Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Vital Therapies with a $18 average price target.

See today’s analyst top recommended stocks >>

Based on Vital Therapies’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $12.68 million. In comparison, last year the company had a GAAP net loss of $12.41 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Vital Therapies, Inc. operates as a biotherapeutic company, which develops a human hepatic cell-based system for the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts